Global Blood Profile

USD 1.85  3.4%

Global Blood exotic insider transaction detected

Global Blood Therapeutics Inc insider trading alert for general transaction of stock option (right to buy) by David Johnson, Chief Commercial Officer, on March 14, 2018. This event was filed by Global Blood Therapeutics with SEC on 2018-03-14. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Global Blood Summary

Global Blood Therapeutics Inc (GBT) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 147 people. Global Blood is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with total capitalization of 2.68 B. Global Blood Therapeutics Inc runs under Healthcare sector within Biotechnology industry. This company has 51.06 M outstanding shares of which 5.17 M shares are currently shorted by investors with about 4.69 days to cover shorted positions. ADVANCED BATTERY has about 314.82 M in cash with (93.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.69.
Check Global Blood Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Global Blood Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Global Blood Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 32% 
Equity ratings for Global Blood Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in USA and traded on NASDAQ. It employs 147 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameGlobal Blood Therapeutics Inc
President CEO, DirectorTed LoveView All
Thematic ClassificationBiotechView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address171 Oyster Point Boulevard
CIK Number01629137.0
Contact Number650 741 7700
CurrencyUSD - US Dollar


Global Blood Analyst Recommendations
Target PriceAdvice# of Analysts
Global Blood Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Global Blood Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Global Blood Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.64April 4, 2017
Global Blood Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Global Blood Corporate Directors
Michael Bonney Director
Mark Perry Independent Director
Philip Pizzo Director, Ph.D